A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

Trial Profile

A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer; Basal cell nevus syndrome; Carcinoma
  • Focus Therapeutic Use
  • Acronyms MIKIE
  • Sponsors Roche
  • Most Recent Events

    • 05 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 07 Feb 2017 Results (Data cut off 27 August, 2015) published in the Lancet Oncology
    • 01 Feb 2017 This trial has been completed in Netherlands as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top